



# **Publishing options: Spanish institution associated authors**



## Key information

### 1. How do we determine eligibility of the article for the Spanish agreement?

- The acceptance date of the article should be on or after 1st January 2021
- The corresponding author must be affiliated with the participating Spanish institution or a faculty/department
- The article must be from an eligible journal

# Key information

## 2. Role of the institutional librarian in the Elsevier OA Platform (EOAP)

- By the time the article in is your EOAP, we have published the first version of the article in ScienceDirect (within 48 hours of acceptance)
- You therefore are not approving the publication of the article, you are validating whether the corresponding author can make use of the APC fund as part of the agreement

**Corresponding author receives an email post acceptance with a unique link to complete the author journey and choose publishing options**

**Author clicks on Complete the Rights and Access information form**

## Author journey demo: Spanish institutions

Corresponding author	Dr. Lee Chahin
E-mail address	leechahin@cphuniv.com
Journal	Fuel
Our reference	JFUE238040
PII	S0016-2361(21)00108-3

**Welcome Dr. Chahin,**

To help us finalize the publication of your article please complete the publishing form(s) below.

**Note:** you will receive a confirmation e-mail after completing each form.

When placing orders via these forms, you may be asked to provide the information listed below.

- **Purchase Order Number**  
If a Purchase Order Number is required for payment by your institution and you already have one, please provide it via the publishing form(s). Note that you may still complete the form(s) now, even if you do not have the Purchase Order number available yet.
- **Tax Exemption Number and Tax Exemption Certificate** if applicable to your institution.

For Bank and company address details, see the [Information you may need to supply to complete the options](#).

## Rights and Access

[Complete the Rights and Access information form](#)

Elsevier supports responsible sharing. To find out how you can share your article, please visit our [Sharing Policy page](#).

For information on author rights visit Elsevier's [Author Rights](#) pages.

For information on publishing open access with Elsevier visit [elsevier.com/openaccess](https://elsevier.com/openaccess).



Corresponding author selects his/her affiliation details which we use to identify the authors and match them to the Spanish agreement

### Author journey demo: Spanish institutions

Corresponding author	Dr. Lee Chahin
E-mail address	leechahin@cphuniv.com
Journal	Fuel
Our reference	JFUE238040
PII	S0016-2361(21)00108-3

### Corresponding Author's Organization ⓘ

Please enter the corresponding author's organization. We use this information so we can offer tailored publishing options and a personalized article publishing charge for Gold open access when applicable.

**Hint:** start your search using your main organization name (e.g. University of Manchester) as this will return the most results from which to select the most appropriate option. If you're unable to find your specific department, then selecting your main organization is sufficient. For more tips on searching for an organization please visit our [Support Center](#).

- Organization name\*
- University of barcelona
  - University of Barcelona**  
Barcelona, ES
  - Autonomous University of Barcelona**  
Barcelona, ES
  - University of Barcelona Faculty of Medicine**  
Barcelona, ES
  - University of Barcelona Faculty of Medicine and Health Sciences**  
Barcelona, ES
  - University of Barcelona Faculty of Physics**  
Barcelona, ES
  - University of Barcelona .**  
Tarragona, ES

Save and Continue >

Copyright ©  
Cookies are :

ions ↗ Help ↗



Corresponding author also adds the co-author affiliation details

### Author journey demo: Spanish institutions

Were there any co-authors for this article?

- Yes  
 No

### Add Co-author Details ⓘ

Please provide details for all co-authors. We use this information so we can offer tailored publishing options and a personalized article publishing charge for Gold open access when applicable.

**Hint:** start the organization search using the main organization name (e.g. University of Manchester) as this will return the most results from which to select the most appropriate option. If you're unable to find the specific department, then selecting the main organization is sufficient. For more tips on searching for an organization please visit our [Support Center](#).

First name or initial\*

John

Last name\*

Head



Organization name\*

KU Leuven

Or use recently selected organization

University of Barcelona +

+ Add another co-author

Previous

Save and Continue >

1

Corresponding  
Author

2

Co-Author

3

Research  
Funders

4

Publishing  
Options

5

Review Order

6

Confirmation

## Author journey demo: Spanish institutions



Did the research in this article receive funding?

 Yes No

## Funder Details ⓘ

To help us determine the best publishing options for your article, please provide details of the organization(s) that funded the research. For tips on searching for an organization please visit our [Support Center](#).

If providing details for two or more organizations, please list the organization(s) that provided the most funding first, as this will help us determine the publishing options for your article.

Organization name\*



Milliman Inc

Grant/Contract numbers\*



GT123

[+ Add grant/contract number](#)[+Add another organization](#)[Previous](#)[Save and Continue >](#)

Author can add the Funder details. Funder can be the affiliated institute or a different one. In this case it is Milliman

Based on information you have provided, your publishing options are shown below


## Gold Open Access

Publish Open Access

Make my published article available to everyone.

As an author affiliated with a University of Barcelona, upon validation, [agreement between the Spanish consortium and Elsevier](#) will cover the APC.

I can share my article in accordance with the user license that I select.

 Institution preferred

Your institution prefers you to publish OA

### Article Publishing Charge (APC)

	Price
	<b>EUR 3320.00</b>
	Institutional Agreement Discount
	<b>- EUR 3320.00</b>
<hr/>	
	To pay (on validation)
	<b>0.00</b>

If your institution cannot confirm your affiliation, you will receive an invoice for the APC of EUR 3,320.00 (ex. VAT). Within 2 weeks of receiving the invoice, you may [contact Researcher Support](#) to publish free of charge under the subscription model.

Personalized publishing options for the Spanish agreement

## Subscription

Publish Subscription

As a corresponding author affiliated with a **Finnish institution** choose to publish my article subscription, making my final published journal article will be immediately available to all journal subscribers, to patients and caregivers, and [other groups](#).


I understand that I must wait 12 months before I can share my accepted manuscript publicly in my institution or funder's repository. I can immediately share it on non-commercial personal homepages and blogs, within my institution, and privately with collaborators.

Previous

Save and Continue >



## Rights and Access



- Elsevier offers two CC licenses for OA
- Author selects the CC License

Author journey demo: Spanish institutions

### Select your user license

Please select your license. If you need to comply with a mandated license and the mandated license is not listed below, please visit our [Support Hub](#) for additional help.

CC BY 4.0

A license to permit readers to share and adapt your article for any purpose, even commercially.

[Read more about CC BY 4.0](#)

CC BY-NC-ND 4.0

A license to permit readers to share all or part of your article in any medium or format for non-commercial purposes. Permission from Elsevier is required for the distribution of derivative versions of the article or for commercial use.

[Read more about CC BY-NC-ND 4.0](#)

Previous

Save and Continue >

1

Corresponding  
Author

2

Co-Author

3

Research  
Funders

4

Publishing  
Options

5

Licenses

6

Rights

7

Publishing  
Agreement

8

Review Order

9

Confirmation

Author journey demo: Spanish institutions



Elsevier Ltd

## Select Your Status

- I am the sole author of the manuscript
- I am one author signing on behalf of all co-authors of the manuscript



Please indicate which of the below applies to you:

- We are all US Government employees and the Article is public domain and therefore the 'License of publishing rights' clause does not apply
- I am a US Government employee but some of my co-authors are not
- I am not a US Government employee but some of my co-authors are
- The work was performed by contractors of the US Government under contract number:

Contract Number\*

- All or some of the authors are UK, Canadian or Australian Government employees and Crown Copyright is asserted
- Some of the authors are employees of the UK, Canadian or Australian Government but Crown Copyright is not asserted
- None of the above
- I am signing as an authorized representative and on behalf of my employer



## Signed on Behalf of Corresponding Author

Please complete this section if you are not the corresponding author as listed above. A copy of the agreement will be sent to you and the corresponding author.


- I am signing on behalf of the corresponding author

Name, job title and company (if employer representative)\*E-mail address\*

Author selects the rights

Previous

Save and Continue &gt;



## System presents author with the Journal License Publishing Agreement

### Author journey demo: Spanish institutions

Elsevier Ltd

#### Your Status

- I am one author signing on behalf of all co-authors of the manuscript

#### License of Publishing Rights

I hereby grant to Elsevier Ltd an exclusive publishing and distribution license in the manuscript identified above and any tables, illustrations or other material submitted for publication as part of the manuscript (the "Article") in print, electronic and all other media (whether now known or later developed), in any form, in all languages, throughout the world, for the full term of copyright, and the right to license others to do the same, effective when the Article is accepted for publication. This license includes the right to enforce the rights granted hereunder against third parties.

#### Supplemental Materials

"Supplemental Materials" shall mean materials published as a supplemental part of the Article, including but not limited to graphical, illustrative, video and audio material.

With respect to any Supplemental Materials that I submit, Elsevier Ltd shall have a perpetual worldwide non-exclusive right and license to publish, extract, reformat, adapt, build upon, index, redistribute, link to and otherwise use all or any part of the Supplemental Materials, in all forms and media (whether now known or later developed) and permit others to do so. The publisher shall apply the same end user license to the Supplemental Materials as to the Article where it publishes the Supplemental Materials with the Article in the journal on its online platforms on an Open Access basis.

#### Research Data

"Research Data" shall mean the result of observations or experimentation that validate research findings and that are published separate to the Article, which can include but are not limited to raw data, processed data, software, algorithms, protocols, and methods.

With respect to any Research Data that I wish to make accessible on a site or through a service of Elsevier Ltd, Elsevier Ltd shall have a perpetual worldwide, non-exclusive right and license to publish, extract, reformat, adapt, build upon, index, redistribute, link to and otherwise use all or any part of the Research Data in all forms and media (whether now known or later developed), and to permit others to do so. Where I have

## Authors agrees to the Journal License Publishing Agreement


- The Article and the Supplemental Materials do not infringe any copyright, violate any other intellectual property, privacy or other rights of any person or entity, or contain any libellous or other unlawful matter.
- I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in the Article or the Supplemental Materials.
- Except as expressly set out in this License Agreement, the Article is not subject to any prior rights or licenses and, if my or any of my co-authors' institution has a policy that might restrict my ability to grant the rights required by this License Agreement (taking into account the Scholarly communication rights permitted hereunder), a written waiver of that policy has been obtained.
- If I and/or any of my co-authors reside in Iran, Cuba, Sudan, Burma, Syria, or Crimea, the Article has been prepared in a personal, academic or research capacity and not as an official representative or otherwise on behalf of the relevant government or institution.
- If I am using any personal details or images of patients, research subjects or other individuals, I have obtained all consents required by applicable law and complied with the publisher's policies relating to the use of such images or personal information. See <https://www.elsevier.com/about/our-business/policies/patient-consent> ↗ for further information.
- Any software contained in the Supplemental Materials is free from viruses, contaminants or worms.
- If the Article or any of the Supplemental Materials were prepared jointly with other authors, I have informed the co-author(s) of the terms of this License Agreement and that I am signing on their behalf as their agent, and I am authorized to do so.

### Governing Law and Jurisdiction

This License Agreement will be governed by and construed in accordance with the laws of the country or state of Elsevier Ltd ("the Governing State"), without regard to conflict of law principles, and the parties irrevocably consent to the exclusive jurisdiction of the courts of the Governing State.

For information on the publisher's copyright and access policies, please see <http://www.elsevier.com/copyright> ↗.

I have read and agree to the terms of the License Agreement.



- This is the summary page explaining the choices the author made in the publishing journey
- Corresponding author and coauthors receive a copy of summary via email
- Articles becomes OA on Science Direct within 24 hours
- Librarian at the institute will receive a notification for validation within 48 hours who then has 3 weeks to complete the validation

Author journey demo: Spanish institutions ▼

### Review Order

Research Funders	Milliman Inc Grant numbers: GT123
Publishing Option	Gold Open Access
User License	CC BY 4.0
Publishing Agreement	<ul style="list-style-type: none"><li>• I am one author signing on behalf of all co-authors of the manuscript</li></ul>

26 February 2021

### Total payment due

Price (excluding taxes)  
**EUR 3320.00**

Institutional Agreement Discount  
**- EUR 3320.00**

---

To pay (on validation)  
**0.00**

 If your institution cannot confirm your affiliation, you will receive an invoice for the APC of EUR 3,320.00 (ex. VAT). Within 2 weeks of receiving the invoice, you may [contact Researcher Support](#) to publish free of charge under the subscription model.

Previous

Finish >



Thank you

